Detailed information for compound 175377

Basic information

Technical information
  • TDR Targets ID: 175377
  • Name: 2-[[2-[fluoro-(4,6,7-trifluoro-1H-benzimidazo l-2-yl)methyl]-3-methylbenzimidazole-5-carbon yl]amino]-3-phosphonopropanoic acid
  • MW: 529.338 | Formula: C20H16F4N5O6P
  • H donors: 5 H acceptors: 8 LogP: 0.3 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 2
  • SMILES: O=C(c1ccc2c(c1)n(C)c(n2)C(c1[nH]c2c(n1)c(F)c(cc2F)F)F)NC(C(=O)O)CP(=O)(O)O
  • InChi: 1S/C20H16F4N5O6P/c1-29-12-4-7(19(30)26-11(20(31)32)6-36(33,34)35)2-3-10(12)25-18(29)14(24)17-27-15-9(22)5-8(21)13(23)16(15)28-17/h2-5,11,14H,6H2,1H3,(H,26,30)(H,27,28)(H,31,32)(H2,33,34,35)
  • InChiKey: CVOFRTRGRUZDMM-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 2-[[2-[fluoro-(4,6,7-trifluoro-1H-benzimidazol-2-yl)methyl]-3-methyl-benzimidazole-5-carbonyl]amino]-3-phosphono-propanoic acid
  • 2-[[[2-[fluoro-(4,6,7-trifluoro-1H-benzimidazol-2-yl)methyl]-3-methyl-5-benzimidazolyl]-oxomethyl]amino]-3-phosphonopropanoic acid
  • 2-[[2-[fluoro-(4,6,7-trifluoro-1H-benzimidazol-2-yl)methyl]-3-methyl-benzimidazol-5-yl]carbonylamino]-3-phosphono-propanoic acid
  • 2-[[2-[fluoro-(4,6,7-trifluoro-1H-benzimidazol-2-yl)methyl]-3-methyl-benzimidazole-5-carbonyl]amino]-3-phosphono-propionic acid
  • AIDS162637
  • N-({2-[Fluoro(4,6,7-trifluoro-1H-benzimidazol-2-yl)methyl]-1-methyl-1H-benzimidazol-6-yl}carbonyl)-3-phosphonoalanine
  • AIDS-162637

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Hepatitis C virus Hepatitis C virus serine protease, NS3/NS4A Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Mycobacterium tuberculosis Membrane-associated phospholipase C 2 PlcB Hepatitis C virus serine protease, NS3/NS4A   54 aa 49 aa 32.7 %
Mycobacterium ulcerans Maf-like protein Hepatitis C virus serine protease, NS3/NS4A   54 aa 44 aa 38.6 %
Leishmania braziliensis hypothetical protein, conserved Hepatitis C virus serine protease, NS3/NS4A   54 aa 46 aa 26.1 %
Toxoplasma gondii hypothetical protein Hepatitis C virus serine protease, NS3/NS4A   54 aa 50 aa 28.0 %
Entamoeba histolytica hypothetical protein Hepatitis C virus serine protease, NS3/NS4A   54 aa 52 aa 23.1 %
Trypanosoma brucei gambiense expression site-associated gene 3 (ESAG3)-like protein, putative Hepatitis C virus serine protease, NS3/NS4A   54 aa 49 aa 28.6 %
Trypanosoma brucei hypothetical protein, conserved Hepatitis C virus serine protease, NS3/NS4A   54 aa 55 aa 30.9 %
Schistosoma japonicum expressed protein Hepatitis C virus serine protease, NS3/NS4A   54 aa 44 aa 29.5 %
Trypanosoma congolense WD40 repeats, putative Hepatitis C virus serine protease, NS3/NS4A   54 aa 46 aa 28.3 %
Echinococcus granulosus 60S ribosomal protein L8 Hepatitis C virus serine protease, NS3/NS4A   54 aa 48 aa 33.3 %
Trypanosoma brucei expression site-associated gene 3 (ESAG3)-like protein Hepatitis C virus serine protease, NS3/NS4A   54 aa 49 aa 28.6 %
Schistosoma mansoni hypothetical protein Hepatitis C virus serine protease, NS3/NS4A   54 aa 44 aa 29.5 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Schistosoma mansoni tyrosine kinase 0.8002 0.436 0.0146
Brugia malayi Protein kinase domain containing protein 0.9731 0.5377 0.5377
Schistosoma mansoni tyrosine kinase 1.7592 1 1
Onchocerca volvulus 0.0588 0 0.5
Onchocerca volvulus 0.0588 0 0.5
Onchocerca volvulus 0.0588 0 0.5
Onchocerca volvulus 0.0588 0 0.5
Toxoplasma gondii PAN domain-containing protein 0.9138 0.5028 1
Onchocerca volvulus 0.0588 0 0.5
Onchocerca volvulus 0.0588 0 0.5
Loa Loa (eye worm) TK/INSR protein kinase 1.7592 1 1
Echinococcus granulosus insulin growth factor 1 receptor beta 1.7592 1 1
Onchocerca volvulus 0.0588 0 0.5
Brugia malayi Furin-like cysteine rich region family protein 0.8002 0.436 0.436
Echinococcus granulosus insulin receptor 1.7592 1 1
Onchocerca volvulus 0.0588 0 0.5
Echinococcus multilocularis epidermal growth factor receptor 0.8002 0.436 0.373
Loa Loa (eye worm) TK/EGFR protein kinase 0.8002 0.436 0.436
Schistosoma mansoni tyrosine kinase 0.8002 0.436 0.0146
Onchocerca volvulus 0.0588 0 0.5
Onchocerca volvulus 0.0588 0 0.5
Toxoplasma gondii PAN domain-containing protein 0.9138 0.5028 1
Echinococcus multilocularis insulin receptor 1.7592 1 1
Echinococcus multilocularis epidermal growth factor receptor 0.8002 0.436 0.373
Loa Loa (eye worm) hypothetical protein 0.959 0.5294 0.5294
Schistosoma mansoni tyrosine kinase 1.7592 1 1
Echinococcus multilocularis insulin growth factor 1 receptor beta 1.7592 1 1
Onchocerca volvulus 0.0588 0 0.5
Schistosoma mansoni tyrosine kinase 0.8002 0.436 0.0146

Activities

Activity type Activity value Assay description Source Reference
Ki (binding) = 0.55 uM Inhibition of HCV serine protease NS3/NS4A in the presence of Zn ChEMBL. 12372517
Ki (binding) = 0.55 uM Inhibition of HCV serine protease NS3/NS4A in the presence of Zn ChEMBL. 12372517
Ki (binding) = 72 uM Inhibition of HCV serine protease NS3/NS4A in the presence of EDTA. ChEMBL. 12372517
Ki (binding) = 72 uM Inhibition of HCV serine protease NS3/NS4A in the presence of EDTA. ChEMBL. 12372517

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.